title: Intravitreal bevacizumab (avastin) combined with vitrectomy for recurrences of proliferative vitreoretinopathy in Von Hippel-Lindau disease.
authors.forename: Ryotaro
authors.initials: R
authors.lastname: Tano
authors.forename: Keigo
authors.initials: K
authors.lastname: Kakurai
authors.forename: Toshiya
authors.initials: T
authors.lastname: Sakurai
authors.forename: Ritsuko
authors.initials: R
authors.lastname: Fujiwara
authors.forename: Tomiya
authors.initials: T
authors.lastname: Mano
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Maeno
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D012008:Recurrence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014821:Vitrectomy; D018630:Vitreoretinopathy, Proliferative / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D006623:von Hippel-Lindau Disease / Q000150:complications* / Q000175:diagnosis
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab